Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05057663
Other study ID # Soh-Med-21-09-03
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date September 1, 2022

Study information

Verified date September 2021
Source Sohag University
Contact Rania Farouk, Resident
Phone 01283074271
Email rania_farouk_post@med.sohag.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Group 1; intralesional injection of bleomycin in plantar wart. Group 2; intralesional injection of 5-fluorouracil in plantar wart


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date September 1, 2022
Est. primary completion date March 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: Subjects must meet all of the following criteria to be considered for participation in this study. 1. Subject is able to comprehend and is willing to sign an informed consent/assent for participation in this study. 2. Male or female = 8 years old. 3. Subject has a clinical diagnosis of common warts. 4. Subject has up to 1 Target Wart and up to 3 additional Non-Target Warts located on the trunk or extremities. The identified Target and Non-Target Warts must meet the requirements as defined below: 1. Each wart must have a longest axis that is = 3mm and = 8 mm and have a thickness of =3mm 2. Each wart must be a discrete lesion 3. Each wart must be present for at least 4 weeks 4. Not be covered with hair which, in the investigator's opinion, would interfere with the study medication treatment or the study evaluations 5. Not be in an intertriginous fold 6. Be the only common wart present when the circular cutout template is centered over the wart 5. The Target and Non-Target Warts must have a PWA = 2. 6. Subject chemistry and complete blood count results are within normal limits. If any of the laboratory values are outside normal range, the treating investigator must assess the value/s as NOT clinically significant and document this in the subject's medical chart in order for the subject to be eligible for randomization. 7. Woman of childbearing potential (WOCBP) must have a negative urine pregnancy test within 14 days of the first application of study drug and agree to use an active method of birth control for the duration of the study. 8. Subject is non-pregnant and non-lactating. 9. Subject is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of any Target or Non-Target Warts or which exposes the subject to an unacceptable risk by study participation. 10. Subject is willing and able to follow all study instructions and to attend all study visits. Exclusion Criteria: Subjects are excluded from this study if any 1 or more of the following criteria is met: 1. Subject has clinically atypical warts on the trunk or extremities. 2. Subject is immunocompromised (e.g., due to chemotherapy, systemic steroids, genetic immunodeficiency, transplant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bleomycin and 5-fluorouracil
In the bleomycin-treated group, bleomycin vial will be diluted first with 5 ml distilled water At time of treatment session 2 ml of lidocaine 2% and 1 ml of the bleomycin stock solution will be taken in 100-unite insulin syringe. Thus, the working bleomycin solution will be used in treatment 1 mg/ml. The bleomycin solution will be injected intralesional till blanching of the wart will be occurred. The amount of injection ranging from 0.2, 0.5, 1 ml according to size of warts; (5 mm, 10 mm, >10 mm) maximum for 1 ml in single wart and 2ml in treatment session. Treatment session will be done every two weeks maximum four sessions. In 5-fluorouracil treated group, 5-fluorouracil vial ( 1 ml of 50 mg/ml 5-FU will be mixed with 0.25 ml of lidcaine 2% Every wart will be injected with 0.1 ml of the previous mixture into it base using an insulin syringe till blanching of the warts maximum 2ml of 5-FU per session. Treatment session will be done every two week for maximum 6 sessions

Locations

Country Name City State
Egypt Sohag Faculty of Medicine Sohag

Sponsors (1)

Lead Sponsor Collaborator
Sohag University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Response to intralesional injection of bleomycin, 5fluorouracil in treatment of plantar wart Physician's Wart Assessment Grade Descriptor 0 Clear: No visible wart. No further treatment is indicated
Near Clear: A visible wart that is less than 3mm in maximal diameter (or length)
A visible wart = 3mm and <6 mm in maximal diameter (or length)
A visible wart = 6mm in maximal diameter (or length)
3monthes
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05324904 - Intralesional Vitamin D3 Versus Intralesional Acyclovir in Treatment of Plantar Warts N/A
Completed NCT00328991 - Clinical Trial Evaluating Efficacy of Duct Tape for Treatment of Warts N/A
Completed NCT05592041 - Studying of Natural Constituents' Treatment of Plantar Warts Early Phase 1
Completed NCT05115669 - Safety & Effectiveness of Wortie Freeze Plus in Common and Plantar Warts N/A
Recruiting NCT06261684 - Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial. Phase 2/Phase 3
Recruiting NCT02151630 - Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts Phase 2/Phase 3
Withdrawn NCT04823845 - Plantar Wart Treatment Using Adapalene Gel Early Phase 1
Completed NCT05588999 - Comparative Study Between Treatment With Cryotherapy Alone Versus Cryotherapy Plus Salicylic Acid Dressing for Planter Warts Phase 1
Completed NCT01536834 - Safety & Performance Study of Verruca Treatment Device N/A
Recruiting NCT05488860 - Piezoelectric Drived Microneedling in Treating Refractory Skin Diseases N/A
Recruiting NCT05520658 - Evaluation of the Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5 - Fluorouracil in Treatment of Plantar Warts N/A
Not yet recruiting NCT04654091 - Cryotherapy VS. Nitric-zinc Complex in the Treatment of Plantar Warts. N/A
Not yet recruiting NCT05599971 - Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in Plantar Warts N/A
Not yet recruiting NCT05198180 - Treatment of Plantar Warts Phase 3
Recruiting NCT06214559 - Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts. N/A
Recruiting NCT03977753 - Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts Phase 4
Completed NCT03183765 - Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Phase 4